B
BioCryst Pharmaceuticals, Inc. (BCRX)
NMS – Real vaqt narxi. Valyuta: USD
8.80
+0.22 (2.56%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
8.80
+0.22 (2.56%)
Yopilishda: May 12, 2026, 4:00 PM EDT
BioCryst Pharmaceuticals, Inc. - bu irsiy angionevrotik shish (IASH) va boshqa kam uchraydigan kasalliklarga davo vositalarini ishlab chiqish va tijoratlashtirish bilan shug'ullanuvchi biotexnologiya kompaniyasidir. Kompaniya RAPIVAB, RAPIACTA va PERAMIFLU nomlari ostida o'tkir murakkab bo'lmagan va mavsumiy grippni davolash uchun vena ichiga yuboriladigan neyraminidaza ingibitori bo'lgan peramivir in'ektsiyasini; va IASHni davolash uchun og'iz orqali qabul qilinadigan serin proteaza ingibitori bo'lgan ORLADEYOni sotadi. Shuningdek, u 1-bosqichda bo'lgan neterton sindromi uchun proteinli terapevtik vosita bo'lgan BCX17725; 1-bosqichda bo'lgan diabetik makula shishi uchun ko'z plazma kallikrein ingibitori bo'lgan Avoralstat; 3-bosqichda bo'lgan IASH uchun monoklonal antitelali plazma kallikrein ingibitori bo'lgan Navenibart; 1-bosqich klinik sinovida bo'lgan neterton sindromini davolash uchun KLK5 ingibitori bo'lgan tadqiqotdagi proteinli terapevtik vosita bo'lgan BCX17725; 1a-bosqich sinovida bo'lgan atopik dermatitni davolash uchun OX40 antagonistli monoklonal antitelasi bo'lgan STAR-0310 ni ishlab chiqmoqda. Kompaniya Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd. va Green Cross Corporation; Milliy allergiya va yuqumli kasalliklar instituti; Biotibbiyotni rivojlantirish bo'yicha ilg'or tadqiqotlar va rivojlanish boshqarmasi; AQSh Sog'liqni saqlash va aholiga xizmat ko'rsatish departamenti; hamda Albert Einstein College of Medicine of Yeshiva University va Industrial Research, Ltd. bilan hamkorlik va litsenziya shartnomalariga ega. BioCryst Pharmaceuticals, Inc. 1986 yilda tashkil etilgan va uning shtab-kvartirasi Shimoliy Karolina shtatining Durham shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. William P. Sheridan MBBS | Chief Development Officer |
| Dr. Yarlagadda S. Babu Ph.D. | Chief Discovery Officer |
| Mr. Babar Ghias | CFO & Head of Corporate Development |
| Mr. Charles K. Gayer | CEO, President & Director |
| Mr. John Ruesch | Chief Technical Operations Officer |
| Mr. Philip George | Chief Strategy Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 8-K | f8k_050626.htm |
| 2026-05-06 | 10-Q | bcrx-20260331.htm |
| 2026-05-04 | 8-K | f8k_050426.htm |
| 2026-04-23 | DEFA14A | ef20071188_defa14a.htm |
| 2026-04-23 | DEF 14A | bcrx-20260423.htm |
| 2026-02-26 | 10-K | bcrx-20251231.htm |
| 2026-01-23 | 8-K/A | f8ka_012226.htm |
| 2026-01-12 | 8-K | f8k_011226.htm |
| 2026-01-09 | 8-K | f8k_010826.htm |
| 2025-12-15 | S-4/A | ny20057110x2_s4a.htm |
| Ms. Alane P. Barnes | Senior VP, Chief Legal Officer & Corporate Secretary |
| Ms. Jinky Ang Rosselli | Chief Data Innovation Officer |
| Ms. Stephanie Angelini | Chief People Officer & Chief Communications Officer |
| Nick Wilder | Manager of Investor Relations |